Editorial
HeartMate 3—a “Step” in the right direction
Abstract
Earlier in this decade, the concerning reports regarding high rates of complications for left ventricular assist devices (LVADs) led to the interruption and finally the premature completion of the REVIVE-IT (Randomized Evaluation of VAD InterVEntion before Inotropic Therapy) trial (1).
